Skip to content
Loading company

Latest annual · FY2022

Millions
Total revenues
0
Gross profit
0
Operating income
(41)
Net income
(41)
Free cash flow
(28)
Open Financials

Key stats

Open Analysis

Compound annual growth

Revenue, 3 yearsFY2019 to FY2022
n/m
Revenue, 5 yearsFY2017 to FY2022
n/m
Net income, 5 yearsFY2017 to FY2022
n/m

Celyad Oncology SA financials: quick answers

Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.

MetricFY2022FY2021ChangeSource
Revenue€0€020-F 2023-03-23 · proof
Gross profit€0€020-F 2023-03-23 · proof
Operating income-€40.9 million-€26.4 million20-F 2023-03-23 · proof
Net income-€40.9 million-€26.5 million20-F 2023-03-23 · proof
Cash from operating activities-€28 million-€26.6 million20-F 2023-03-23 · proof
Free cash flow-€28.1 million-€27 million20-F 2023-03-23 · proof
Total assets€19.7 million€79.9 million-75.3%20-F 2023-03-23 · proof
Total liabilities€15.4 million€36.3 million-57.6%20-F 2023-03-23 · proof
Cash and cash equivalents€12.4 million€30 million-58.5%20-F 2023-03-23 · proof
Total debt€020-F 2023-03-23 · proof
What was Celyad Oncology SA's revenue in fiscal 2022?
Celyad Oncology SA reported revenue of €0 for fiscal 2022 (the year ended Dec 31, 2022), against €0 the year before. Source: the 20-F filed with the SEC on Mar 23, 2023. SEC
What was Celyad Oncology SA's gross profit in fiscal 2022?
Celyad Oncology SA reported gross profit of €0 for fiscal 2022 (the year ended Dec 31, 2022), against €0 the year before. Source: the 20-F filed with the SEC on Mar 23, 2023. SEC
What was Celyad Oncology SA's operating income in fiscal 2022?
Celyad Oncology SA reported operating income of -€40.9 million for fiscal 2022 (the year ended Dec 31, 2022), against -€26.4 million the year before. Source: the 20-F filed with the SEC on Mar 23, 2023. SEC
What was Celyad Oncology SA's net income in fiscal 2022?
Celyad Oncology SA reported net income of -€40.9 million for fiscal 2022 (the year ended Dec 31, 2022), against -€26.5 million the year before. Source: the 20-F filed with the SEC on Mar 23, 2023. SEC
What was Celyad Oncology SA's cash from operating activities in fiscal 2022?
Celyad Oncology SA reported cash from operating activities of -€28 million for fiscal 2022 (the year ended Dec 31, 2022), against -€26.6 million the year before. Source: the 20-F filed with the SEC on Mar 23, 2023. SEC
What was Celyad Oncology SA's free cash flow in fiscal 2022?
Celyad Oncology SA reported free cash flow of -€28.1 million for fiscal 2022 (the year ended Dec 31, 2022), against -€27 million the year before. Source: the 20-F filed with the SEC on Mar 23, 2023. SEC
What are Celyad Oncology SA's total assets?
As of Dec 31, 2022, Celyad Oncology SA reported total assets of €19.7 million, against €79.9 million a year earlier (-75.3%). Source: the 20-F filed with the SEC on Mar 23, 2023. SEC
What are Celyad Oncology SA's total liabilities?
As of Dec 31, 2022, Celyad Oncology SA reported total liabilities of €15.4 million, against €36.3 million a year earlier (-57.6%). Source: the 20-F filed with the SEC on Mar 23, 2023. SEC
What are Celyad Oncology SA's cash and cash equivalents?
As of Dec 31, 2022, Celyad Oncology SA reported cash and cash equivalents of €12.4 million, against €30 million a year earlier (-58.5%). Source: the 20-F filed with the SEC on Mar 23, 2023. SEC
What is Celyad Oncology SA's total debt?
As of Dec 31, 2022, Celyad Oncology SA reported total debt of €0. Source: the 20-F filed with the SEC on Mar 23, 2023. SEC

Read from the FinancialMD API on Nov 13, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.

The same numbers for an agent, with proof on every value:

curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=cik:1637890&period_type=annual&limit=5"

Information only, not investment advice.